Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 12;36(14):e88.
doi: 10.3346/jkms.2021.36.e88.

Predictive Role of Endoscopic Surveillance after Total Gastrectomy with R0 Resection for Gastric Cancer

Affiliations

Predictive Role of Endoscopic Surveillance after Total Gastrectomy with R0 Resection for Gastric Cancer

Jung Su Lee et al. J Korean Med Sci. .

Abstract

Background: Endoscopic surveillance after total gastrectomy (TG) for gastric cancer is routinely performed to detect tumor recurrence and postoperative adverse events. However, the reports on the clinical benefits of endoscopic surveillance are ambiguous. We investigated the clinical benefit of endoscopic surveillance after TG for gastric cancer.

Methods: We analyzed 848 patients who underwent TG with R0 resection for gastric cancer between 2011 and 2012 (380 early gastric cancer and 468 advanced gastric cancer) and underwent regular postoperative surveillance with endoscopy and abdominopelvic computed tomography (CT) with contrast.

Results: Median follow-up periods were 58 months for both endoscopy (range, 3-96) and abdominopelvic CT (range, 1-96). Tumor recurrence occurred in 167 patients (19.7%), of whom seven (4.2%) were locoregional recurrences in the peri-anastomotic area (n = 5) or regional gastric lymph nodes (n = 2). Whereas the peri-anastomotic recurrences were detected by both endoscopy and abdominopelvic CT, regional lymph node recurrences were only detected by abdominopelvic CT. Out of the 23 events of postoperative adverse events, the majority (87%) were detected by radiologic examinations; three events of benign strictures in the anastomotic site were detected only by endoscopy.

Conclusion: Endoscopic surveillance did not have a significant role in detecting locoregional tumor recurrence and postoperative adverse events after TG with R0 resection for gastric cancer. Routine endoscopic surveillance after TG may be considered optional and performed according to the capacities of each clinical setting.

Keywords: Endoscopy; Gastric Cancer; Locoregional Recurrence; Postoperative Adverse Events; Surveillance; Total Gastrectomy.

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1. Flowchart of patient enrollment and follow-up results.
TG = total gastrectomy, EGC = early gastric cancer, AGC = advanced gastric cancer.
Fig. 2
Fig. 2. The distribution of patients and patterns of recurrence over time. (A) The distribution of patients according to the follow-up period. (B) The patterns and timing of recurrence in the 167 patients. Values in the histogram represent the number of patients.
Fig. 3
Fig. 3. Endoscopic and contrast abdominopelvic CT findings of peri-anastomotic recurrence. The photos are each from patient #1 through patient #5 (left to right) in Table 2. (A) Mass of irregular shape around the anastomotic site. (B) Asymmetric low attenuated wall thickening at the anastomotic site. (C) Irregular nodularity with hyperemia on proximal part of the efferent loop. (D) Ill-defined low-density mass in the posterolateral aspect of the anastomotic site. (E) Irregular ulcerative lesion with luminal narrowing at the anastomotic site. (F) Wall thickening with enhancement just distal to the E-J anastomotic area. (G) Stricture of the anastomotic site with irregular mucosal nodularity. (H) Wall thickening with enhancement in the anastomotic site. (I) Irregular nodularity with hyperemia on the proximal part of the efferent loop. (J) Wall thickening with an enhancement of jejunum below the anastomotic site.
CT = computed tomography, E-J = esophagojejunal.

Similar articles

Cited by

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. - PubMed
    1. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, et al. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014;50(7):1330–1344. - PubMed
    1. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291(2):187–194. - PubMed
    1. Park HA, Nam SY, Lee SK, Kim SG, Shim KN, Park SM, et al. The Korean guideline for gastric cancer screening. J Korean Med Assoc. 2015;58(5):373–384.
    1. Hamashima C, Shibuya D, Yamazaki H, Inoue K, Fukao A, Saito H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol. 2008;38(4):259–267. - PubMed